High-risk stage III-IV melanoma patients treated with pembrolizumab report better quality of life

By | November 24, 2022
Patients with high-risk stage III-IV melanoma who received pembrolizumab after their surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon.